|
|
| |
VeriChip Corporation to Exhibit Its VeriTrace System at
American Academy of Forensic Sciences Conference
Other topics:
UHF
RFID Reader,
RFID Tracking Mandate,
RFID Security Solutions
VeriChip Corporation
February 19, 2008
Delray Beach, FL -- VeriChip Corporation (the “Company”) (NASDAQ:
CHIP), a provider of radio frequency identification (RFID) systems
for healthcare and patient-related needs, will be exhibiting at the
American Academy of Forensic Sciences (AAFS) 60th Anniversary
Scientific Meeting in Washington, D.C. from February 20-22. The
conference, which will take place at the Marriott Wardman Park
Hotel, is the premier event for forensic science professionals and
the industry’s source for cutting-edge information. The Company will
demonstrate its VeriTrace™ System to coroners, medical examiners and
other forensics experts during the conference, which has generated a
majority of VeriTrace sales historically. |
| |
|
|
| |
VeriTrace is designed to assist state and
federal agencies in the management of emergency situations and
disaster recovery using implantable RFID technology. The VeriTrace
System includes an implantable RFID microchip, a VeriTrace
Bluetooth™ handheld reader, a customized Ricoh 500SE Digital Camera
capable of receiving both RFID scanned data and GPS data wirelessly,
and a Web-enabled database for gathering and storing information and
images captured during emergency response operations. This database
ensures the precise collection, storage and inventory of all data
and images related to remains and the associated evidentiary items.
The Web-enabled database also allows the recreation of an accurate
and complete reconstruction of a disaster setting, crime scene or
similar setting where recreation is necessary.
About VeriChip
VeriChip Corporation, headquartered in Delray
Beach, Florida, develops, markets and sells RFID systems used to
identify, locate and protect people and assets. VeriChip's goal is
to become the leading provider of RFID systems for people in the
healthcare industry. The Company recently began marketing its
VeriMed(TM) Patient Identification System, a passive RFID system for
rapidly and accurately identifying people who arrive in an emergency
room and are unable to communicate. This system uses the first
human-implantable passive RFID microchip, the implantable VeriChip(TM),
cleared for medical use in October 2004 by the United States Food
and Drug Administration.
For more information on VeriChip, please call 1-800-970-2447, or
email info@verichipcorp.com. Additional information can be found
online at http://www.verichipcorp.com.
Statements about the Company's future expectations, including growth
of the business and success of the Company’s marketing and sales
initiative, and all other statements in this press release other
than historical facts are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E of
the Securities Exchange Act of 1934, and as that term is defined in
the Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to change
at any time, and the Company's actual results could differ
materially from expected results. Information about factors that
could affect the Company’s business is set forth in the Company’s
various filings with the Securities and Exchange Commission,
including those set forth in the Company’s 10-K filed on April 2,
2007, under the caption “Risk Factors.” The Company undertakes no
obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law. |
| |
|
|
